PIK3CD and neoplasm: Moreover, anti-tumor immune responses were increased by an inactivating mutation (D910A mutation) in phosphatidylinositol-3-kinase (PI3K) p110δ or a knockout of PI3K in T-regs in mice, without autoimmunity in the mutant mice [155].